title: Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.
authors.forename: Claudia
authors.initials: C
authors.lastname: Martorell
authors.forename: Eileen
authors.initials: E
authors.lastname: Theroux
authors.forename: Arlene
authors.initials: A
authors.lastname: Bermudez
authors.forename: Jane
authors.initials: J
authors.lastname: Garb
authors.forename: Debra
authors.initials: D
authors.lastname: Kronschnabel
authors.forename: Katrina
authors.initials: K
authors.lastname: Oie
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D002219:Carbamates / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D010755:Organophosphates / Q000009:adverse effects* / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012189:Retrospective Studies; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D010755:Organophosphates; D013449:Sulfonamides; C426859:fosamprenavir